Search
Showing results for "lung disease preterm"
Results of an innovative clinical trial led by Perth researchers have shown that the drug interferon could help reduce the spread of COVID-19 from a positive person to their household contacts, with the study helping to inform treatment options for a future pandemic.
The Wal-yan Respiratory Research Centre's dedicated team members, along with special guests, embarked on a journey to Wadjemup (Rottnest Island) on 9 and 10 November.
We are excited to announce the winners of our inaugural Illuminate Awards
We suggest that 37 weeks' gestation may not be the optimal cutoff for defining perinatal risk as it applies to behavioural development.
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
In 2016, with enabling donations from Denby Roberts, Stan Perron, Wesfarmers and Centurion, the Institute established a permanent presence in the Kimberley.
Multidrug-resistant tuberculosis is uncommon in Australia
Congratulations to three outstanding The Kids Research Institute Australia researchers who have received second chance WA health funding designed to support researchers who have narrowly missed out on highly competitive national funding.
Since the discovery of MECP2 duplication syndrome (MDS) in 1999, efforts to characterise this disorder have been limited by a lack of large datasets, with small case series often favouring the reporting of certain conditions over others. This study is the largest to date, featuring 134 males and 20 females, ascertained from the international MECP2 Duplication Database (MDBase).
Helen Jenny Leonard Downs MBChB MPH BApplSci (physio) MSc PhD Principal Research Fellow Head, Child Disability +61 419 956 946 08 6319 1763